Prof. Marek Trněný: Update on the GOYA study – ICML 2017
Prof. Marek Trněný on his research on mantle cell lymphoma
Prof. Marek Trněný: DLBCL patients superior ≥ 80y treated with anthracycline-based chemotherapy
Prof. Marek Trněný discusses highlights from 13-ICML 2015
Prof. Marek Trneny | EBMT 2018 | What were the most interesting results from EBMT?
ASH 2014: Phase II SPRINT study of lenalidomide in relapsed/refractory mantle cell lymphoma
Marek Trněný | Retrospective CLSG analysis on biopsy-proven FL transformation in the rituximab era
Prognostic indices for follicular lymphoma: PRIMA-PI
A question of age: how should elderly DLBCL patients be treated?
Prof. Marek Trněný | ASH 2017 | R-CHOP plus rituximab maintenance in elderly patients
02. prof. MUDr. Marek Trněný, CSc. (23. kongres EHA)
Message to mantle cell lymphoma physicians and patients
Results of Phase III GADOLIN trial for follicular lymphoma
Marek Trneny | Was the PRIMA PI prognostic index feasible in a real-world cohort of FL patients?
Phase II study of Lenalidomide Vs Best Investigator’s in Choice Relapsed/Refractory MCL
iwNHL 2017 highlights: the PDX model
Improving outcomes for R/R DLBCL with polatuzumab vedotin
Marek Trněný | Riziko histologické transformace u nemocných s FL - retrospektivní analýza
What can be done about early relapse in DLBCL?
V ordinaci - Marek Trněný 3/8
